News

Precision Biologics to Deliver two Oral Presentations on our Clinical and Scientific Programs at the World Immunotherapy Conference, March 2-4, 2020, San Diego, CA

Dr Massimo Fantini, Senior Scientist is Presenting the following Talk entitled: "Mechanisms of action of...

The National Cancer Institute Opens Clinical Trial Testing Safety and Dosing of NEO-201 Antibody in Patients with Advanced Cancer

Clinical trial tests safety and dosing of NEO-201 antibody in patients with advanced cancer

Precision Biologics manuscript on our NEO-201 Antibody article published in Frontiers in Immunology

Preclinical Characterization of a Novel Monoclonal Antibody NEO-201 for the Treatment of Human Carcinomas

Precision Biologics to Highlight Preclinical Data on NEO-201, a Neoantigen Targeting Antibody in Oral Presentation at the 110th Annual Meeting of the American Association of Clinical Research

Rockville, MD, April 2, 2017 - Precision-Biologics Inc.

2016 ASCO Annual Meeting – A phase 2 study of NEO-102 (ensituximab), a novel chimeric monoclonal antibody, in adult patients (pts) with unresectable, metastatic colorectal cancer (mCRC).

VIEW THE POSTER

Precision Biologics to Present Combination Immunotherapy of a Novel NEO-Epitope Antibody Targeting Ovarian and Uterine Cancer at the AACR Annual Meeting 2016

New Orleans. LA– April 17, 2016 — Precision Biologics, a clinical stage biotechnology company...